Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells

Correction to: International Journal of Hematology (2020) 112:316–330 https://doi.org/10.1007/s12185-020-02916-8

In the original publication of the article, the figures 4 C, F and 5 B, C were published with unexpected appearance of dots. The corrected Figs. 4, 5 are given in this correction.

In addition, Y.M.’s grant should be “18K08323/Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology in Japan”.

Fig. 4

Menatetrenone does not affect the differentiation or proliferation capabilities of BM-MSCs. a, b Osteogenic differentiation of BM-MSCs treated with or without menatetrenone, as assessed by Alizarin Red S staining (a). Red nodules indicate mineralization (b). Representative images are shown. c Expression levels of osteogenesis-associated genes in BM-MSCs treated with or without menatetrenone, as assessed by qRT-PCR. RUNX2 runt-related transcription factor 2, OSX osterix, COL collagen, ALP alkaline phosphatase, OPN osteopontin, OCN osteocalcin. d, e Adipogenic differentiation of BM-MSCs treated with or without menatetrenone, as assessed by Oil Red O staining (d). Red-staining indicates fat-laden cells (e). Representative images are shown. f The proliferation of BM-MSCs treated with or without menatetrenone. a, c, d, f Data are represented as the mean ± SD; n = 5 per group; n.s. not significant

Fig. 5

Direct cell–cell interactions, but not soluble factors, mediate enhanced HPC expansion in co-cultures with menatetrenone-treated human BM-MSCs. a Cytokine arrays of supernatants from cultures of BM-MSCs treated with 0, 1, or 10 µM menatetrenone. CCL2 C–C motif chemokine ligand 2, CXCL12 C-X-C motif chemokine ligand 12, MIF macrophage migration inhibitory factor, SERPINE1 serpin family E member 1, IL-6 interleukin-6. b The mRNA expression levels of multiple hematopoiesis-associated genes in BM-MSCs treated with 0 µM (black bars), 1 µM (gray bars), or 10 µM (white bars) menatetrenone, as assessed by qRT-PCR; n = 5 per group. Ang-1 angiopoietin-1, FLT3L fms-related tyrosine kinase 3 ligand, G-CSF granulocyte colony-stimulating factor, IL-6 interleukin-6, IL-11 interleukin-11, Jag-1 jagged-1, LIF leukemia inhibitory factor, M-CSF macrophage colony-stimulating factor, SCF stem cell factor. c Co-culture of CD34⁺ HSPCs with BM-MSCs treated with 0 (black bars), 1 (blue bars), or 10 µM (gray bars) menatetrenone in the presence (+, red squares) or absence (−) of cell culture inserts (n = 4 per group). Flow cytometry analyses showing the numbers of CD45⁺ cells, CD34⁺ cells, CD34⁺CD38⁻ cells, and CD34⁺CD38⁺ cells. d Co-culture of CD34⁺ HSPCs with BM-MSCs treated with 0, 1, or 10 µM menatetrenone in the presence (red bars) or absence (black bars) of cell culture inserts (n = 4 per group). Flow cytometry plots showing the percentages of CD34⁻CD33⁺ cells, CD34⁻CD13⁺ cells, and CD34⁻CD41a⁺ cells. b–d Data are presented as the mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant